Dyadic International Inc.
DYAIDyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.
- Revenue
- −61.4%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +0.80%
Quarter to September 2026, against a year earlier
Follow DYAI
Alert me
Dyadic International Inc. (DYAI) Return on invested capital
Dyadic International Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −380.1% (fiscal 2018) to 26.7% (fiscal 2016); the current reading is higher than 82% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 353.37 |
| FY2019 | −353.4% | 26.74 |
| FY2018 | −380.1% | (400.81) |
| FY2017 | 20.7% | (6.04) |
| FY2016 | 26.7% | 26.74 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NCEL NewcelX Ltd. compare | 0.00% |
| QNTM Quantum Biopharma Ltd. compare | 0.00% |
| ALLR Allarity Therapeutics, Inc. compare | 0.00% |
| LSTA Lisata Therapeutics, Inc. compare | 0.00% |
| ALGS Aligos Therapeutics, Inc. compare | 0.00% |
| DYAI Dyadic International Inc. | 0.00% |
| NEUP Neuphoria Therapeutics Inc. compare | −232.7% |
| PLUR Pluri Inc. compare | −690.2% |
| MCRB Seres Therapeutics, Inc. compare | −1,267.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)